Cell and Gene Therapy Market to Grow by USD 6.56 Billion (2024-2028), Driven by Rising Prevalence of Chronic Diseases, AI-Powered Report Explores Market Evolution - Technavio [Yahoo! Finan...
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
to grow by USD 6.56 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 14.76% during the forecast period. Increasing prevalence of chronic diseases is driving market growth, with a trend towards strategic alliances. However, high cost and failure rate in clinical trials poses a challenge.Key market players include Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., bluebird bio Inc., Bristol Myers Squibb Co., Castle Creek Biosciences Inc., CORESTEM Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Ferring BV, Gilead Sciences Inc., Helixmith Co. Ltd., Human Stem Cells Institute, JCR Pharmaceticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, Orchard Therapeutics Plc, Pfizer Inc., Sibiono GeneTech Co. Ltd., and Vericel Corp.. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Forecast period Base Year
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was downgraded by analysts at Wolfe Research from a "peer perform" rating to an "underperform" rating.MarketBeat
- Antisense & RNAi Therapeutics Market Overview 2024-2030 - Global Antisense & RNAi Therapeutics Market Forecast to Reach $14.4 Billion by 2030 [Yahoo! Finance]Yahoo! Finance
- RFK Jr. could play a big role under Trump—and Big Pharma is sounding the alarm: ‘We need somebody grounded by science and evidence, not somebody who rejects it' [Yahoo! Finance]Yahoo! Finance
- RFK Jr. could play a big role under Trump—and Big Pharma is sounding the alarm: ‘We need somebody grounded by science and evidence, not somebody who rejects it' [Fortune]Fortune
- High Growth Tech Stocks To Watch In November 2024 [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 10/31/24 - Beat
ALNY
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- 10/31/24 - Form 10-Q
- ALNY's page on the SEC website